Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
Phase 4
Completed
NCT05548647
| Condition | Obesity |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | University of Pennsylvania |
|---|
| Status | Completed |
|---|
| Enrollment | 120 participants |
|---|
| Interventions | Behavioral Treatment, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] |
|---|
| Start date | Jul 26, 2022 |
|---|
| Completion date | May 12, 2025 |
|---|
| Results posted | Aug 3, 2026 |
|---|
Summary
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S1: Change from baseline to weeks 20, 40, and 60 · kcal
| Behavioral Treatment + Placebo (Weeks 0-60) | -75.1 ± 52.6 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -367.0 ± 37.2 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | -76.8 ± 73.8 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -317.0 ± 49.7 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | 69.6 ± 73.9 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -200.0 ± 50.1 kcal |
|---|
| p-value | <0.0001 |
|---|
| Mean Difference (Net) | 291.9 (95% CI 164.0–419.8) |
|---|
Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S2: Endpoint comparison at week 72 · kcal
| Continuous Placebo (Weeks 60-72) | 1073.0 ± 71.1 kcal |
|---|
| Medication (Semaglutide) Switched to Placebo (Weeks 60-72) | 951.8 ± 42.9 kcal |
|---|
| Continued Medication (Semaglutide) (Weeks 60-72) | 657.7 ± 81.5 kcal |
|---|
| p-value | 0.1513 |
|---|
| Mean Difference (Final Values) | 121.2 (95% CI -46.0–288.4) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.